Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
29 févr. 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
28 févr. 2024 09h15 HE
|
Virios Therapeutics
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
15 févr. 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Numerous reports indicate that the fibromyalgia treatment market is positioned to continue to grow at a...
Fibromyalgia Treatment Market Projected to Surpass US$ 2.7 Billion in Revenue by 2033, According to Persistence Market Research
18 janv. 2024 09h45 HE
|
Persistence Market Research
New York, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global revenue from the fibromyalgia treatment market stands at US$ 1.3 billion in 2022, with the global market expected to grow...
Cannabidiol Market Size Worth USD 46.47 Billion in 2032 | Emergen Research
15 nov. 2023 12h21 HE
|
Emergen Research
Vancouver, Nov. 15, 2023 (GLOBE NEWSWIRE) -- The global Cannabidiol (CBD) market size was USD 3.86 Billion in 2022 and is expected to register a rapid revenue CAGR of 28.3% during the forecast...
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 nov. 2023 07h05 HE
|
Virios Therapeutics
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on...
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
06 nov. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral...
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
12 oct. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat...
NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia
02 oct. 2023 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
18 sept. 2023 07h05 HE
|
Virios Therapeutics
ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...